Key result
Malignancies represent 60%-85% of superior vena cava syndrome etiologies, with non-Hodgkin lymphoma accounting for 10% of all cases.
Case Report
Highlights that low-grade follicular lymphoma can initially present as superior vena cava syndrome.
SVCS evaluation should include lymphoma subtypes; case extends recognized presentations but leaves open validation in larger cohorts.
Superior vena cava (SVC) syndrome refers to a constellation of symptoms produced by the obstruction of blood flow through the SVC, resulting in symptoms of dyspnea, facial and upper-extremity edema, cough, chest pain, and dysphagia.1 Malignancies represent 60%-85% of the etiologies of SVC syndrome. Cumulatively, lymphoma and lung cancer represent 95% of malignancy-related SVC syndrome etiologies, with non-small-cell lung cancer (NSCLC) reported in about 50% of cases, small-cell lung cancer (SCLC) in about 25%, and non-Hodgkin lymphoma (NHL) in 10 % of all cases.
No takes yet. Share an insight, caveat, or question.
Grant et al. (2014) conducted a case report in Superior vena cava syndrome and low-grade follicular lymphoma. Malignancies represent 60%-85% of superior vena cava syndrome etiologies, with non-Hodgkin lymphoma accounting for 10% of all cases.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: